Highest-materiality recent filing
Bret Christensen resigns as CEO effective June 8, 2026 for personal/family reasons; remains a Class III director.
Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall
Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.
Biote Q4 revenue $46.4M; net income $2.6M; anticipates procedure growth H2 2026
Q4 2025 revenue $46.4M, gross margin 68.0%; net income $2.6M ($0.06 diluted EPS), down from $3.5M ($0.10) in Q4 2024.
Biote Q3 2025: Revenue $48.0M, net income $9.2M ($0.22 EPS), down YoY
Revenue $48.0M, gross profit margin 71.8%.
Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%
Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.
Biote Q1 net income $15.8M vs loss, revenue $49.0M, restructuring 16 employees
Net income of $15.8M ($0.37 diluted EPS) vs net loss of $(5.7M) ($(0.12) per share) in Q1 2024.
CEO Terry Weber retires; Bret Christensen named new CEO effective Feb 1, 2025
Terry Weber resigns as CEO and director, effective Feb 1, 2025; becomes Strategic Advisor.
Biote Q3 revenue $51.4M (+12.8% YoY); EPS $0.33; Adj. EBITDA $16.2M
Revenue of $51.4M, up 12.8% YoY; procedure revenue $37.9M.
Biote Q2 revenue $49.2M, net loss narrows to $10.5M; procedure revenue grows 7.8% sequentially
Revenue of $49.2M; procedure revenue $38.4M, up 7.8% QoQ vs 6.6% in Q1.
biote settles stockholder litigation with $60M share repurchase agreement
Repurchased ~4.1M Paired Interests for $30M on June 28, 2024.
Biote settles stockholder litigation with $60M share repurchase and earnout cancellation
Repurchases ~8.3M shares from Marci Donovitz for $60M ($7.23 avg) over 3 years.
Biote reports Q1 revenue $46.8M (+4.4%), net loss narrows to $5.8M; reaffirms 2024 guidance
Revenue $46.8M (+4.4% YoY); procedure revenue $37.4M (+6.6%).
Biote settles founder litigation, repurchases all 18.4M shares for ~$76.9M
Repurchases 18.4M shares at $4.17 avg price; $32.2M paid on April 26, remainder over 3 years.
Biote Q4 revenue $45.7M (+2.7% YoY), net income $12.1M; FY adj. EBITDA $55.3M (+10.2%)
Q4 procedure revenue $34.9M (+6.6%); gross margin 69.4% (up >400 bps); diluted EPS $0.18.
Biote settles founder litigation, to repurchase 18.4M shares for $76.9M at $4.17 each
Repurchases 5.1M Class A shares and 13.3M Paired Interests from founder Donovitz for $76.9M total.
Biote announces $20M share repurchase authorization
On Jan 25, 2024, board approved first-ever $20M share repurchase program for Class A common stock.
Biote lowers FY2023 revenue guidance to $185-187M; acquires Asteria Health for $8.5M
FY2023 revenue expected $185-187M (prior guidance $190-200M lower end); Adjusted EBITDA $54-56M (prior $56-60M).
Biote Q3 revenue $45.6M (+8.5% YoY); net income $19.6M; Adj. EBITDA $14.0M
Revenue $45.6M (+8.5% YoY) driven by procedure revenue growth of 7.4% and supplement growth of 5.1%.
Biote Q2 revenue up 19% to $49.3M; FY2023 guidance narrowed to lower end
Revenue $49.3M (+19.1% YoY) driven by procedure (+9.8%) and supplement (+52.8%) growth; gross margin 67.9% (+60 bps).
Biote completes warrant exchange; 97.5% of public warrants tendered, warrant amendment enacted
8,191,336 public warrants (97.5%) and 4,464,900 private warrants (87.4%) validly tendered in exchange offer.
biote Corp. selling stockholder sells 5.2M shares at $5.35 in underwritten secondary offering
Selling stockholder offered 5,217,392 shares of Class A common stock at $5.35 per share; underwriter partially exercised option for additional 576,108 shares.
Biote Q1 revenue $44.8M (+20.7%), net loss $21.4M; launches warrant exchange offer
Revenue $44.8M (+20.7% YoY); gross margin 69.1% (+220 bps).
Biote reports record FY2022 revenue $165M, Q4 adj EBITDA up 40%; guides FY2023 rev $190-200M
Q4 revenue $44.5M (+18.5%), net income $12.8M, diluted EPS $0.18; adjusted EBITDA $13.1M (+40%).
biote Corp. restating 2022 Q2/Q3 results; earnout liability error, EPS revision
Audit committee determined Q2 and Q3 2022 unaudited financials should no longer be relied upon due to earnout valuation error.
Biote Q3 revenue $42M (+18% YoY); expects upper end of 2022 guidance
Revenue $42.0M, up 18% YoY; net loss $(6.3)M, GAAP diluted EPS $(1.74) due to transaction costs.
Biote wins Nasdaq relisting approval; trading resumes Aug 29 under BTMD and BTMDW
Application to relist on the Nasdaq Global Market approved; effective at market open on August 29, 2022.
Biote appoints Samar Kamdar as CFO; Robbin Gibbins to transition out by Nov 15
Samar Kamdar named CFO effective Aug 24, 2022; reports to CEO Terry Weber.
Biote corrects Q2 2022 net income down $9.4M; operating loss widened by $9.4M on omitted deal costs
Corrected Q2 2022 net income $40.3M (was $49.7M); operating loss $(85.6M) (was $(76.2M)).
Biote Q2 revenue up 19% to $41.4M; raises adjusted EBITDA guidance to $47-51M
Revenue $41.4M (+19% YoY); net income $49.7M (includes $79M stock comp and $123M earnout adjustment).
Nasdaq Panel to delist biote Corp. on July 20; company plans appeal and OTC Pink Market trading
Nasdaq Panel determined to delist BTMD Class A common stock and warrants for non-compliance with Round Lot Holder and Market Value of Unrestricted Publicly Held Shares requirements.
Company entered Amended and Restated Investor Rights Agreement allowing it to waive lock-up restrictions at its sole discretion.
On June 12, 2026, in connection with his appointment as Interim Chief Executive Officer, Mr. Peterson and BioTE entered into an amended and restated employment agreement
On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.
On May 27, 2026, the Board of Directors (the “Board”) of biote Corp. (the “Company”) accepted the resignation of Bret Christensen, the Company’s Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC (“BioTE”), effective as of June 8, 2026.
Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen’s resignation, and as a director of the Board, each effective June 8, 2026 (the “Effective Date”).
On June 5, 2025, the Board of Directors (the “Board”) of biote Corp. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee, appointed Richard R. Barrera to serve as a member of the Board to fill the vacancy created by the prior resignation of Steven J. Heyer
vacancy created by the prior resignation of Steven J. Heyer
On June 2, 2025, Steven J. Heyer notified the Board of Directors (the “Board”) of biote Corp. (the “Company”) of his resignation as a member of the Board, effective immediately.
On April 1, 2025 (the “Effective Date”), Marc Beer, biote Corp.’s (the “Company”) Executive Chairman, transitioned from full-time employment to part-time employment (the “Transition”), consistent with the Board of Directors’ transition plan of leadership.
appointed Bret Christensen as Chief Executive Officer (principal executive officer) of the Company and as a member of the Board to fill the vacancy created by Ms. Weber’s resignation, effective as of the Effective Date.
accepted the resignation of Teresa S. Weber, the Company’s Chief Executive Officer, from all positions she holds with the Company, including stepping down from the Board, effective as of February 1, 2025
On July 2, 2024, biote Corp. (the “Company”) announced that Mary Puncochar, who has served as the Company’s Head of Strategic Sales & Business Analytics since March 2024 and, prior to that, served as Chief Commercial Officer from May 2023 to March 2024, was terminated other than for cause from all employment and officer positions with the Company.
Samar Kamdar, the Company’s current Chief Financial Officer, will transition out of his role, effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event earnings